Everest Medicines Announces First Patient Dosed in ASCEND Phase 2b Trial of VIS-101 in Wet AMD

提供:PR Newswire
※本記事は、当サイトの提携先である「PR Newswire」からのプレスリリースを掲載したものです。

SHANGHAI, Nov. 20, 2026 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, announced that the first patient has been treated in the ASCEND study, a randomized Phase 2b trial evaluating two doses of VIS-101 (6 mg and 9 mg) head-to-head against 2 mg aflibercept in approximately 244 treatment-naïve patients with wet age-related macular degeneration (wet AMD). The study is being conducted in China in partnership with Visara, Inc., a majority-owned ophthalmology subsidiary of NovaBridge Biosciences, Inc. (NASDAQ: NBP).

ASCEND’s primary efficacy endpoint is the change in best-corrected visual acuity (BCVA) from baseline to Week 36 versus aflibercept dosed every eight weeks. The goal of the ASCEND study is to determine the dose(s) to advance into VIS-101’s global Phase 3 program based on safety, efficacy and durability.

VIS-101 is a purpose-designed tetravalent, dual VEGF-A x ANG-2 inhibitor in development for retinal vascular diseases, including wet AMD, diabetic macular edema (DME) and retinal vein occlusion (RVO). In the randomized, dose ranging Phase 2a study, VIS-101 demonstrated rapid, robust, and durable treatment responses in wet AMD, along with a favorable safety profile. Approximately 50% of patients in the 6 mg treatment-naïve cohort remained retreatment-free six months after the last loading dose.

Wet AMD affects more than 20 million people globally[1]. In China, the prevalent patient population of AMD and DME exceeds 15 million, with around 600,000 new cases each year, yet only about 500,000 patients currently receive treatment.

"Patients with wet AMD and other retinal vascular diseases have significant unmet needs, as treatment burden remains a meaningful challenge for both patients and physicians," said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. "Dosing the first patient in the Phase 2b ASCEND study marks an important step in the clinical development of VIS-101. With encouraging efficacy, safety and durability results observed in Phase 2a, we believe VIS-101 has the potential to offer longer intervals between injections and sustained disease control. ASCEND will further evaluate this potential against an established standard of care, with findings supporting future global development.

Our established clinical and commercial capabilities across China and other Asian markets will enable us to accelerate efforts to bring VIS-101 to patients and make this innovative therapy available to more patients."

On October 30, 2025, Everest Medicines entered into a collaboration agreement with Visara, under which Everest acquired an exclusive license to develop, manufacture, and commercialize VIS-101 in Greater China, Singapore, South Korea, and certain Southeast Asian countries.

About the ASCEND Phase 2b Trial

ASCEND is a randomized, quadruple-masked, active-controlled, head-to-head Phase 2b study (NCT07798375) to evaluate the safety and efficacy of VIS-101 (aka AM712 or ASKG712) in approximately 244 treatment naïve patients with wet AMD in China. Patients will be randomized to either 6 mg or 9 mg VIS-101, or 2 mg aflibercept, a standard-of-care anti-VEGF therapy. All patients will initially receive three monthly doses of either VIS-101 or aflibercept and can then be retreated based on protocol-specified retreatment criteria that are the same for all groups up to Month 9. The main objectives are to determine the dose(s) to be studied in Phase 3 clinical trials and establish the initial durability with treatment intervals up to seven months after three loading doses.

About VIS-101

VIS-101 (also known as ASKG712 or AM712), is a dual VEGF-A X ANG-2 inhibitor in development for the treatment of retinal vascular diseases, such as wet AMD, diabetic macular edema (DME) and retinal vein occlusion (RVO). VIS-101’s bispecific, tetravalent design format provides more binding sites and increased VEGF-A and ANG-2 affinity and avidity, for rapid, robust and durable responses. VIS-101 has completed initial safety and dose-escalation studies in both the US and China and a randomized, dose-ranging 2a study in China (NCT05456828). VIS-101 is currently being evaluated in the dose-determining Phase 2b ASCEND study, with initiation of the global Phase 3 program planned as early as 2027.

About Everest Medicines

Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative pharmaceutical products that address critical unmet medical needs for patients in global markets. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies. The Company owns a global manufacturing base of commercial scale in Jiashan, Zhejiang Province, and has established a comprehensive GMP production quality management system in accordance with China, EU, and WHO standards.

The Company’s therapeutic areas of focus include autoimmune, ophthalmology, critical care, and CKM (cardiovascular, kidney, and metabolic) diseases. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Its pharmaceutical distribution capabilities further complement its existing manufacturing and commercialization operations, supporting efficient product supply and delivery to the market.

Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion.

For more information, please visit the Company’s website: www.everestmedicines.com. 

Forward-Looking Statements

This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.

Source information:

  1. Invest Ophthalmol Vis Sci. 2021 Nov 24; 62 (14): 26. doi: 10.1167/iovs.62.14.26
スポンサーリンク